Horizon Pharma

Horizon Pharma Plc
Public limited company
Traded as NASDAQ: HZNP
Industry Healthcare
Founded 2005
Headquarters Dublin, Ireland
Key people

Timothy P. Walbert (Chairman, President & CEO)
Paul W. Hoelscher (CFO)
Robert F. Carey (CBO)
John J. Kody (CCO)

Jeffrey W. Sherman, M.D. (CMO)
Decrease$264 million (2014)[1]
Website www.horizonpharma.com

Horizon Pharma Public Limited Company (NASDAQ: HZNP) is a specialty pharmaceutical company that develops and markets medicine through its subsidiaries in the United States. The company was founded in 2005 and is based in Dublin, Ireland. The company focuses on developing treatments for arthritis, pain and inflammatory diseases.[2] Horizon's product portfolio includes Actimmune (interferon gamma), Duexis (ibuprofen + famotidine), Pennsaid (dilofinac, 2% topical), and Rayos/Lodotra (prednisone).[3]

Business

The company lead product base includes DUEXIS and RAYOS. Outside the United States, RAYOS is also known as LODOTRA.[4]

The company has cooperated with American Gastroenterological Association (AGA) Institute to launch a program named “Connect to Protect” which aims to help physicians and patients better understand non-steroidal anti-inflammatory drug (NSAID) risks. The program is planned to promote communications between physicians and patients about NSAIDs and gastrointestinal ulcers.[5]

In March 2014, the company completed the acquisition of Vidara Therapeutics International through a merge valued at about $660 million.[6]

In October 2014, the company acquired the U.S. sales and marketing rights to the osteoarthritis drug Pennsaid from Nuvo Research for $45 million.[7]

In March 2015, the company acquired Hyperion Therapeutics for $1.1 billion, increasing Horizons orphan disease drug portfolio.[8]

In December 2015, the company acquire Crealta Holdings for $510 million.[9]

References

External links

This article is issued from Wikipedia - version of the Tuesday, January 26, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.